How are health systems in Asia promoting evidence-based policies for healthy aging?

Life expectancy in Japan, South Korea, and much of urban China has now outpaced that of the United States and other high-income countries. With this triumph of longevity, however, comes a rise in the burden of noncommunicable diseases (NCDs) like diabetes and hypertension, reducing healthy life years for individuals in these aging populations, as well as challenging the healthcare systems they rely on for appropriate care.

The challenges and disparities are even more pressing in low- and middle-income economies, such as rural China and India. Moreover, the COVID-19 pandemic has underscored the vulnerability to newly emerging pathogens of older adults suffering from NCDs, and the importance of building long-term, resilient health systems.

What strategies have been tried to prevent NCDs—the primary cause of morbidity and mortality—as well as to screen for early detection, raise quality of care, improve medication adherence, reduce unnecessary hospitalizations, and increase “value for money” in health spending?

Fourteen concise chapters cover multiple aspects of policy initiatives for healthy aging and economic research on chronic disease control in diverse health systems—from cities such as Singapore and Hong Kong, to large economies such as Japan, India, and China.

KAREN EGGLESTON is the director of the Stanford Asia Health Policy Program and deputy director of the Shorenstein Asia-Pacific Research Center at the Freeman Spogli Institute for International Studies at Stanford University. Eggleston earned her PhD in public policy from Harvard University. Eggleston studied in China and was a Fulbright scholar in Korea. Her research focuses on government and market roles in the health sector and Asia health policy, especially in China, India, Japan, and Korea; healthcare productivity; and the economics of the demographic transition.
Healthy Aging in Asia
HEALTHY AGING IN ASIA

Edited by Karen Eggleston

Stanford | Walter H. Shorenstein
Asia-Pacific Research Center
Freeman Spogli Institute
Contents

Tables and Figures vii
Abbreviations xi
Contributors xv
Preface and Acknowledgements xxiii

1 Healthy Aging in Asia: Introduction
Karen Eggleston 1

2 Healthy Aging and Inequality in Age of Death:
Comparing Trends in Japan, Korea, Singapore,
and the United States
Karen Eggleston, Victor R. Fuchs, Daejung Kim,
and Zhi Ping Teo 13

3 Healthy Aging and Economic Research on the Net
Value of Noncommunicable Disease Management
in Japan
Chiyo Hashimoto and Karen Eggleston 41

4 The Political Economy of Precision Health:
The Case of Japan
Minori Ito 65

5 Personalized and Precision Medicine in Japan
Hokuto Asano 87

6 Diabetes Care Management and Policy toward
Healthy Aging in South Korea
Hongsoo Kim 99
7 Noncommunicable Disease Management in Hong Kong: Current Policies and the Potential Role of Economics Research
Janet Tin Kei Lam, Sabrina Wong, and Jianchao Quan

8 Creating National Demonstration Areas for the Integrated Prevention and Control of Noncommunicable Diseases in China
Jianqun Dong, Fan Mao, Wenlan Dong, Yingying Jiang, Shiwei Liu, and Maigeng Zhou

9 Avoidable Admission Rates for Diabetes Patients and Associated Medical Spending in Rural China: Evidence from Zhejiang Province

10 Exploring and Promoting the Family Doctor System in an Aging China
Rize Jing and Hai Fang

11 Hypertension Control after Health Insurance Expansion: Empirical Evidence from China
Jason Li

12 Private Roles for Public Goals in China’s Social Services
Jack Donahue, Karen Eggleston, Yijia Jing, and Richard J. Zeckhauser

13 Cancer, Disparities, and Public-Private Roles
Karen Eggleston, Jui-fen Rachel Lu, Christina Ping, and Nancy Zhang

14 Healthy Aging Policies in India
Kavita Singh and Dorairaj Prabhakaran

Appendix: Methods for Estimating Net Value of Chronic Disease Management

Index
# Tables and Figures

## Tables

2.1 Inequality in age-of-death in Japan, Korea, Singapore, and the United States as measured at the 20th and 80th percentiles of the distribution, 1950 and 2010  

2.2 Mean age-of-death at the 20th and 80th percentiles of the distribution, by sex, across OECD countries and within Japan and the United States  

2.3a U.S. life expectancy at birth for four race-sex groups, 1970 and 2010 (years)  

2.3b Percent of each race–sex group with life expectancy at birth below the median of the total U.S. population, 1970 and 2010  

2.4a Correlation between province characteristics and measures of inequality in age-of-death in Korea, 2008, 2011, 2014, and 2017  

2.4b Correlation between Japanese prefecture characteristics and measures of inequality in age-of-death, 2010  

3.1 Health outcomes, Japan vs. OECD average, 2015  

3.2 Example goals of Healthy Japan 21  


5.1 Four approved cancer drugs and companion diagnostics in clinical practice  

5.2 General information on four approved cancer drugs  

5.3 Price of four approved cancer drugs in Japan and the United Kingdom  

5.4 Approval dates and price of companion diagnostics
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.5</td>
<td>Genetic tests covered under public insurance and their costs</td>
<td>93</td>
</tr>
<tr>
<td>6.1</td>
<td>A health profile of Korea at five points in time, 1980–2015</td>
<td>101</td>
</tr>
<tr>
<td>6.2</td>
<td>Top ten causes of death in Korea, 2000–17 (per 100,000 people)</td>
<td>102</td>
</tr>
<tr>
<td>6.3</td>
<td>Diabetes and hypertension management trends in Korea</td>
<td>103</td>
</tr>
<tr>
<td>6.4</td>
<td>Medical care utilization of people with diabetes in Korea (all ages)</td>
<td>105</td>
</tr>
<tr>
<td>7.1</td>
<td>Public sector charges for various medical services, by eligibility for subsidization</td>
<td>124</td>
</tr>
<tr>
<td>7.2</td>
<td>Current and projected medical costs atributo some NCDs in the public healthcare sector in Hong Kong</td>
<td>131</td>
</tr>
<tr>
<td>8.1</td>
<td>Evaluation index system for national demonstration areas</td>
<td>144</td>
</tr>
<tr>
<td>8.2</td>
<td>Qualification standards for national demonstration areas, by region (points)</td>
<td>145</td>
</tr>
<tr>
<td>8.3</td>
<td>Coverage rates of national demonstration areas in prefecture-level cities</td>
<td>147</td>
</tr>
<tr>
<td>8.4</td>
<td>Coverage rates of national demonstration areas at county/district level</td>
<td>147</td>
</tr>
<tr>
<td>10.1</td>
<td>Establishment of the family doctor system in China</td>
<td>159</td>
</tr>
<tr>
<td>10.2</td>
<td>General practitioners in China, 2012–17</td>
<td>163</td>
</tr>
<tr>
<td>10.3</td>
<td>GP cultivation goals in various provinces or municipalities</td>
<td>166</td>
</tr>
<tr>
<td>10.4</td>
<td>Services provided by China’s family doctor system</td>
<td>169</td>
</tr>
<tr>
<td>10.5</td>
<td>Distribution of service contract fees in Hangzhou and Xiamen</td>
<td>170</td>
</tr>
<tr>
<td>10.6</td>
<td>China’s four representative family doctor system models</td>
<td>174</td>
</tr>
<tr>
<td>11.1</td>
<td>Study sample characteristics</td>
<td>189</td>
</tr>
<tr>
<td>11.2</td>
<td>Community-level linear model results for diagnosis, treatment, and control</td>
<td>191</td>
</tr>
<tr>
<td>11.3</td>
<td>Logistic regression results for diagnosis and control of hypertension</td>
<td>192</td>
</tr>
<tr>
<td>11.4</td>
<td>Logistic regression results for treatment of hypertension</td>
<td>192</td>
</tr>
<tr>
<td>12.1</td>
<td>Population and per capita GDP of the 17 cities in the sample, 2011</td>
<td>202</td>
</tr>
<tr>
<td>13.1</td>
<td>Crude mortality rates (per 100,000) for liver cancer in China, 1990–92 and 2004</td>
<td>221</td>
</tr>
</tbody>
</table>
Prevalence of acute morbidities among the elderly (by age and sex), 2015
Elderly care services in India

Figures

1.1 Life expectancy at birth, 2013 (in years)
1.2 Changes in the Healthcare Access and Quality (HAQ) Index, 1990–2016
2.1 Distribution of age-of-death in the United States, total population (1900–02, 1949–51, and 2010)
2.2a Decreasing inequality in age-of-death in Japan at the 20th and 80th percentiles of the distribution, by sex, 1947–2016
2.2b Decreasing inequality in age of death in Korea at the 20th and 80th percentiles of the distribution, by sex, 1970–2016
2.3a Korean causes of death by age, 2014 (percent share)
2.3b U.S. causes of death by age and sex, 2014 (percent share)
2.4a Age-of-death at the 20th and 80th percentiles of the distribution for the total population of 31 OECD countries, 2010
2.4b Age-of-death at the 20th and 80th percentiles of the distribution for males in OECD countries, 2010
2.4c Age-of-death at the 20th and 80th percentiles of the distribution for females in 32 OECD countries, 2010
2.5a Inequality in male age-of-death and poverty rate by Japanese prefecture, 2010
3.1 Healthcare expenditure in Japan and OECD 35, 2003–16
3.2a Japan’s FY2018 medical and long-term care benefit expenses, projected to FY2025 and FY2040
3.2b Japan’s FY2018 financing of medical and long-term care benefit expenses, projected to FY2025 and FY2040
4.1 The precision health cycle
5.1 The process for determining insurance coverage for drugs in Japan
8.1 National demonstration area application and review process
9.1 Hospitalization expenditures per managed diabetes patient for diabetes-related hospitalizations (top panel) and for all hospitalizations (bottom panel), by patient’s sex and age (2015 USD) 153
9.2 Diabetes patients’ hospitalizations and related healthcare expenditures, by sex, 2015 154
11.1 China’s hypertension care cascade, 2011–13 190
13.2 Main care hospitals for breast cancer patients in Taiwan, by type, 2004–15 228
13.3 Rate of inpatient admissions to private hospitals by province, PRC, 2011–16 229
14.1 Percentage of elderly people across states in India, 1991–2011 239
14.2 Disabilities among India’s elderly (60 years and over) by gender, 2011 241
## Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACSC</td>
<td>ambulatory care-sensitive condition</td>
</tr>
<tr>
<td>AMED</td>
<td>Agency for Medical Research and Development</td>
</tr>
<tr>
<td>AMI</td>
<td>acute myocardial infarction</td>
</tr>
<tr>
<td>AOD</td>
<td>age-of-death</td>
</tr>
<tr>
<td>ASIRC</td>
<td>age-standardized incidence rate</td>
</tr>
<tr>
<td>BKPAI</td>
<td>Building Knowledge Base on Population Ageing in India</td>
</tr>
<tr>
<td>CCSV</td>
<td>Community Care Service Voucher</td>
</tr>
<tr>
<td>CDC</td>
<td>center for disease control</td>
</tr>
<tr>
<td>CDM</td>
<td>chronic disease management</td>
</tr>
<tr>
<td>CDR</td>
<td>cancer detection rate</td>
</tr>
<tr>
<td>CGAT</td>
<td>Community Geriatric Assessment Teams</td>
</tr>
<tr>
<td>CHARLS</td>
<td>China Health and Retirement Longitudinal Study</td>
</tr>
<tr>
<td>CHC</td>
<td>community health center</td>
</tr>
<tr>
<td>CHCC</td>
<td>Community Health Call Centre (Hong Kong)</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>CIR</td>
<td>cancer incidence rate</td>
</tr>
<tr>
<td>COPD</td>
<td>chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>CSIRO</td>
<td>Commonwealth Scientific and Industrial Research Organization</td>
</tr>
<tr>
<td>CSSA</td>
<td>Comprehensive Social Security Assistance (Hong Kong)</td>
</tr>
<tr>
<td>CVD</td>
<td>cardiovascular disease</td>
</tr>
<tr>
<td>DALYS</td>
<td>disability-adjusted life-years</td>
</tr>
</tbody>
</table>
DM  diabetes mellitus
DRAH  diabetes-related avoidable hospitalization
EHCV  Elderly Health Care Voucher (Hong Kong)
EHI  Employees’ Health Insurance (Japan)
GDHP  Global Digital Health Partnership
GP  general practitioner
HAQ  Healthcare Access and Quality (Index)
HBV  hepatitis B virus
HCV  hepatitis C virus
HIRA  Health Insurance Review & Assessment Service (Korea)
HMD  Human Mortality Database
HPV  human papilloma virus
HRS  Health and Retirement Study
HTA  Health Technology Assessment
JDS  Japan Diabetes Society
JMA  Japan Medical Association
JMPT  joint management by three professionals
KAM  Korean Academy of Medical Sciences
KCDC  Korea Centers for Disease Control and Prevention
KDA  Korea Diabetes Association
KDB  Kokuho Database
KNHANES  Korea National Health and Nutrition Examination Survey
KPI  key performance indicator
LDP  Liberal Democratic Party (Japan)
LMIC  low- and middle-income country
LYG  life-years gained
MCI  mild cognitive impairment
METI  Ministry of Economy, Trade and Industry (Japan)
MEXT  Ministry of Education, Culture, Sports, Science, and Technology (Japan)
MHLW  Ministry of Health, Labour and Welfare (Japan)
NATCM  National Administration of Traditional Chinese Medicine (China)
NCD  noncommunicable (chronic) disease
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCMS</td>
<td>New Rural Cooperative Medical System (China)</td>
</tr>
<tr>
<td>NCSP</td>
<td>National Cancer Screening Program (Korea)</td>
</tr>
<tr>
<td>NDB</td>
<td>National Insurance Claim and Health Checkup Database (Japan)</td>
</tr>
<tr>
<td>NGO</td>
<td>non-governmental organization</td>
</tr>
<tr>
<td>NHC</td>
<td>National Health Commission (China)</td>
</tr>
<tr>
<td>NHI</td>
<td>National Health Insurance (Taiwan and Japan)</td>
</tr>
<tr>
<td>NHIS</td>
<td>National Health Insurance Services (Korea)</td>
</tr>
<tr>
<td>NHS</td>
<td>National Health Service</td>
</tr>
<tr>
<td>NICE</td>
<td>National Institute for Health and Care Excellence</td>
</tr>
<tr>
<td>OECD</td>
<td>Organisation for Economic Cooperation and Development</td>
</tr>
<tr>
<td>OOP-PD</td>
<td>out-of-pocket expenditure for prescription drugs</td>
</tr>
<tr>
<td>OWPH</td>
<td>One-way Permit Holders</td>
</tr>
<tr>
<td>P4P</td>
<td>pay-for-performance</td>
</tr>
<tr>
<td>PC-CDM</td>
<td>Primary Care-Chronic Disease Management</td>
</tr>
<tr>
<td>PEP</td>
<td>Patient Empowerment Programme (Hong Kong)</td>
</tr>
<tr>
<td>PMDA</td>
<td>Pharmaceutical and Medical Device Agency (Japan)</td>
</tr>
<tr>
<td>PPM</td>
<td>personalized and precision medicine</td>
</tr>
<tr>
<td>PPP</td>
<td>public-private partnerships</td>
</tr>
<tr>
<td>QALY</td>
<td>quality-adjusted life-years</td>
</tr>
<tr>
<td>RAMP</td>
<td>Risk Factor Assessment and Management Programme (Hong Kong)</td>
</tr>
<tr>
<td>RCHE</td>
<td>residential care home for the elderly</td>
</tr>
<tr>
<td>RCSV</td>
<td>Residential Care Service Voucher (Hong Kong)</td>
</tr>
<tr>
<td>SD</td>
<td>standard deviation</td>
</tr>
<tr>
<td>SES</td>
<td>socioeconomic status</td>
</tr>
<tr>
<td>SHC</td>
<td>specific health checkup</td>
</tr>
<tr>
<td>SHG</td>
<td>specific health guidance</td>
</tr>
<tr>
<td>SHCSHG</td>
<td>specific health checkups and specific health guidance</td>
</tr>
<tr>
<td>UEBMI</td>
<td>Urban Employee Basic Medical Insurance (China)</td>
</tr>
<tr>
<td>URBMI</td>
<td>Urban Resident Basic Medical Insurance (China)</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
Chapter 1

Karen Eggleston is a senior fellow at the Freeman Spogli Institute for International Studies (FSI) at Stanford University, director of the Stanford Asia Health Policy Program, and deputy director of the Shorenstein Asia-Pacific Research Center at FSI. She is also an affiliate of the National Bureau of Economic Research. Eggleston earned her PhD in public policy from Harvard University, after completing MA degrees in economics and Asian studies from the University of Hawaii and a BA in Asian studies summa cum laude (valedictorian) from Dartmouth College. She studied in China for two years and was a Fulbright scholar in Korea. Her research focuses on government and market roles in the health sector; Asia health policy; healthcare productivity; and the economics of the demographic transition. She served as an adviser to the Asia Pacific Observatory on Health Systems and Policies and as a consultant to the World Bank, Asian Development Bank, and WHO regarding health system reforms in the PRC.

Chapter 2

Victor Fuchs is the Henry J. Kaiser, Jr., Professor of Economics and of Health Research and Policy, emeritus at Stanford University. He received a BS in business administration from New York University, and an MA and PhD in economics from Columbia University. Fuchs is a member of the Institute of Medicine and was president (1995) and distinguished fellow (1990) of the American Economic Association. He received the Distinguished Investigator Award (1988) and the Distinguished Fellow Award (1996) from the Association for Health Services Research, and was awarded the Baxter Foundation’s Health Services Research Prize (1991). Fuchs uses economic
theory to provide a framework for the collection and analysis of healthcare data. He has been particularly interested in the role of physician behavior and financial incentives in determining healthcare expenditures, as well as the role of attitudes and beliefs in public support for national health insurance.

DAEJUNG KIM is a research fellow at the Korea Institute for Health and Social Affairs. He received a PhD in economics from Toulouse School of Economics, Toulouse University. Kim is an executive fellow at the Korean Association of Health Economics and Policy. He is interested in health industry regulation and health expenditure.

ZHI PING TEO graduated from Stanford University in 2019 with a master’s degree in East Asian studies and a bachelor’s degree in political science. She is passionate about the intersections between public policy and addressing societal challenges such as health inequities. Her thesis studied China’s Belt and Road Initiative, particularly the political and economic logic of partner countries’ decision-making processes. Her interests include international relations and institutions, and she has worked at the United Nations Mechanism for International Criminal Tribunals and with UN Women/ASEAN. She works at the Ministry of Defense in Singapore.

Chapter 3

CHIYO HASHIMOTO is a research assistant at APARC at Stanford University, working on a wide variety of topics related to healthcare policy in Japan. She has worked as a health economics researcher at a private institute in Japan. She received a BA in Occidental history from the University of Tokyo, and a master of public policy from Hitotsubashi University, focusing on health economics. She published a paper based on her master’s thesis, “Installation and Utilization of MRI scanners in Japan” (in Japanese), and co-authored a working paper, “The Welfare Consequences of Free Entry in Vertical Relationships: The Case of the MRI Market.”

Chapter 4

MINORI ITO earned an MA from Stanford University in international policy and economics. Her current research focuses on the economics of technology and econometric methods for analyzing technology’s impact on industrial structure and efficiency. Her capstone project was on the global economic impacts of artificial intelligence and value chain analysis, and another project focused on the impacts of technology and robots on healthcare in Japan. Prior to Stanford, she worked at the Ministry of Foreign Affairs of Japan,
focusing on multilateral negotiations. She received the bachelor of laws from Keio University, while also studying abroad at Georgetown University.

Chapter 5

**Hokuto Asano** is an official of the Government of Japan. Since joining the government, he has worked for the Railway Division, Real Estate Division, and Cabinet Secretariat. Currently, he is a deputy director in charge of the G20 Tourism Ministerial Meeting. He is interested in the financial sustainability of Japan’s healthcare system. He has written a paper on “Equivalence Scales, the Cost of Children, and the Cost of Living in Japan’s Public Assistance System.” He received bachelor’s and master’s degrees in economics from the University of Tokyo, and the master of arts in international policy studies from Stanford University.

Chapter 6

**Hongsoo Kim** is a professor at the Graduate School of Public Health at Seoul National University (SNU), South Korea. Her research areas include aging and health policy, long-term care systems, and health system performance assessment. She was formerly the scientific committee chair of the Korean Academy of Long-term Care, the Korean Gerontological Society, and the Korean Society of Health Policy and Administration, as well as a 2016–17 Fulbright Visiting Scholar and Takemi Fellow in International Health at the Harvard School of Public Health. She received her PhD from New York University, where she worked as assistant professor before she joined SNU.

Chapter 7

**Janet Tin Kei Lam** is a doctor in training; she expects to receive her medical degree and master of public health (specializing in health economics, policy and management) from the University of Hong Kong in 2020. She previously worked as a research assistant at the School of Public Health, University of Hong Kong; has received a presentation prize at the WONCA conference; and has published in the *European Journal of Health Economics*.

**Sabrina Ching Tung Wong** is a doctor in training; she expects to receive her medical degree from the University of Hong Kong in 2020. She previously worked as a research assistant at the School of Public Health, University of Hong Kong, and has been a reviewer for the *International Journal of Rheumatic Diseases*. She is especially interested in health inequity and the chronic care model.
Jianchao Quan joined the School of Public Health in 2013, and was appointed clinical assistant professor in 2017 at the University of Hong Kong. He graduated with a degree in medicine from the University of Oxford. After his clinical training in London, he specialized in public health and subsequently obtained an MPH with Distinction. He received his BA and MA in medical sciences (infection and immunity) from the University of Oxford, and his postgraduate degree in economics from the University of Hong Kong. His research interest lies in the economic analysis of healthcare services and health policy.

Chapter 8

Jianqun Dong is a professor at the National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention. Dr. Dong graduated from Peking Union Medical College/Chinese Academy of Medical Sciences with a doctoral degree in epidemiology and biostatistics. He graduated from Heidelberg University in the 1990s with a master of science. Dr. Dong has dedicated himself to noncommunicable disease epidemiology, community health, and health promotion for many years. He has had a number of enriching experiences in international academic exchanges and cooperation.

Fan Mao is an MS and MD candidate and assistant researcher working in the Department of Chronic Disease Prevention and Evaluation, National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention. He is devoted to chronic disease prevention and health promotion, as well as the evaluation and scaling up of public health programs.

Wenlan Dong is a chief physician at the National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention. Dr. Dong has for years been greatly involved in noncommunicable disease risk factor control, health promotion, disease burden, and health resource studies, and she has published many scientific papers and monographs.

Yingying Jiang is an associate researcher at the Department of Comprehensive Prevention and Evaluation, National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention. She has an MS in public health and has long been engaged in the field of chronic disease prevention and control,
community-based intervention, and health promotion.

**Shiwei Liu** is a professor of epidemiology and director of the Division of Comprehensive Intervention of Noncommunicable Disease and Evaluation, National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention. He received his PhD in epidemiology and biostatistics from Peking Union Medical College in 2009. His current work and research interests focus on the epidemiology of noncommunicable diseases (NCDs), comprehensive strategies of NCD control and prevention, NCD intervention using mobile health technology, the evaluation of public health policy or intervention, and burden of disease study.

**Maigeng Zhou** is an MD, professor/senior researcher, and deputy director of the National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention. Dr. Zhou is a core member on the expert panel for the Global Burden of Disease. He has presided over numerous research studies, such as a study of environment pollution and health in the Huai River, the effects on health of climate change, the relationship between air pollution and health, a study of the sub-national burden of disease in China, and has published many papers in journals including *Lancet*, the *New England Journal of Medicine*, *JAMA*, and *BMJ*.

**Chapter 9**

**Min Yu** is deputy director of the Zhejiang Provincial Center for Disease Control and Prevention. He was awarded as one of the New-Century 151 Talents of Zhejiang Province, China. He is a committee member of the epidemiology branch of the Chinese Preventive Medicine Association. He is a leader in the key discipline of noncommunicable diseases (NCD) epidemiology and led the establishment of the NCDs and behavioral risk factor surveillance system in Zhejiang Province. Yu earned his medical degree at Zhejiang University and the master of public health at Peking Medical University. Currently, his research focuses on the epidemiology of NCDs, strategy for NCD control and prevention, and disease burden.

**Yiwei Chen** earned his PhD in economics from Stanford University. His research focuses on identifying and addressing important policy questions in healthcare systems across the United States and China. His work has won the “Rising Star” prize in health economics, which is awarded to the top health economics papers from the 2018–19 academic job market by the
Becker Friedman Institute at the University of Chicago. Prior to his doctoral study, he obtained his bachelor’s degree in economics from the University of Chicago and was a management consultant at TGG Group, LLC.

HUI DING is a PhD candidate in economics at Stanford University. She received the bachelor’s degree in economics and psychology from Peking University. Her current work mainly focuses on health economics in both the United States and China. In particular, she is interested in the supply side of the healthcare market, as well as in the role of insurance in containing costs, promoting new technology, adjusting patients’ and providers’ behavior, and affecting health outcomes.

JIEMING ZHONG graduated from the school of public health of Zhejiang University and received the master of public health from the Chinese Center for Disease Control and Prevention. He is the director of the Department of Noncommunicable Disease Control and Prevention in the Zhejiang Center for Disease Control and Prevention (CDC). He served as deputy director of the Department of Tuberculosis Control and Prevention in the Zhejiang CDC during 2008–14. Zhong is a member of the Zhejiang Preventive Medicine Association and has engaged in and chaired several international cooperation and local research projects. He has conducted in-depth research on the control and prevention of NCDs and tuberculosis.

RUYYING HU graduated with a BA from Tongji Medical College of Huazhong University of Science and Technology. She is the deputy director of the Department of Noncommunicable Disease (NCD) Control and Prevention in the Zhejiang Center for Disease Control and Prevention and has been leading the work on NCD surveillance in Zhejiang Province. She is a member of the Disability Prevention and Control Committee of the Chinese Preventive Medicine Association and has led several national and local research projects. She has conducted in-depth research on disease burden and diabetes control and prevention.

CHUNMEI WANG graduated with a BA from Wenzhou Medical University. She is the deputy director of Tongxiang County Center for Disease Control and Prevention and the deputy section chief of Tongxiang Health Bureau. She is a deputy chief technician and skilled in noncommunicable disease control and prevention.
KAIXU XIE graduated with a BA from Wenzhou Medical University. He is a researcher at the Noncommunicable Disease Control and Prevention Department in Tongxiang County Center for Disease Control and Prevention. He is a deputy chief physician of public health and skilled in noncommunicable disease control and prevention.

XIANGYU CHEN is a public health physician and working staff member at the Noncommunicable Disease Control and Prevention Department in the Zhejiang Provincial Center for Disease Control and Prevention. Chen’s ongoing areas of research include the development of risk prediction models using health check-up data, and the cost-effectiveness evaluation for flu shots among individuals with diabetes. He completed his MS in epidemiology and BA in preventive medicine at Soochow University.

PEDRO GALLARDO recently graduated from Stanford University with a BA in East Asian studies, with a concentration of coursework focused on the Chinese healthcare system. Gallardo is interested in the interplay of culture, language, and health, especially as it relates to noncommunicable chronic diseases. He has explored this interest through work in Chinese public health initiatives, serving as a Spanish interpreter through multiple channels, and managing a free health clinic. He hopes to continue his work in health advocacy through a career in medicine.

Chapter 10

RIZE JING is currently a PhD candidate in the School of Public Health at Peking University. He received the master of public health degree from Peking University in 2018. Mr. Jing’s research areas include health economics, health policy, and health system research, and focus on analyses of primary health care, hospital efficiency, health insurance, and health economics evaluation in China. His PhD thesis studies family physician behaviors and impacts on clinical outcomes in China. He has published more than 10 peer-reviewed Chinese and English research articles.

HAIFANG is a professor of health economics at Peking University. He received the master of public health and the PhD in economics from the State University of New York at Stony Brook in 2006. Prior to teaching at Peking University, he taught at the University of California, Davis; the University of Miami; and the University of Colorado, Denver. Dr. Fang’s research areas include health economics, vaccine economics, and health policy. He has published 80 peer-reviewed articles in English and has been
the principle investigator for 20 research grants from the National Natural Science Foundation of China, Gates Foundation, and British Medical Research Council, among others.

Chapter 11

JASON LI is a medical student at Harvard Medical School interested in population health and health equity. He holds a BS in human biology with honors from Stanford and was a U.S. Fulbright Fellow at Shaanxi Normal University in China, where he conducted research on healthcare quality, access, and reform in rural China. During his time at Stanford, Li worked on public health projects at Peking University, Xinan University, and at the White House Initiative on Asian Americans and Pacific Islanders.

Chapter 12

JOHN D. DONAHUE is the Raymond Vernon Senior Lecturer in Public Policy, Kennedy School, Harvard University. He is also faculty chair of the Master in Public Policy (MPP) Program and the SLATE Curriculum Initiative Co-Chair for Cases and Curriculum. His teaching, writing, and research mostly deal with public sector reform and with the distribution of public responsibilities across levels of government and sectors of the economy, including extensive work with the HKS-HBS joint degree program. Donahue has consulted for business and governmental organizations, including the National Economic Council, the World Bank, and the RAND Corporation, and serves as a trustee or advisor to several nonprofits. A native of Indiana, he holds a BA from Indiana University and an MPP and PhD from Harvard.

YIJIA JING is a professor in public administration and associate director of foreign affairs at Fudan University. He is the editor-in-chief of Fudan Public Administration Review, and serves as the vice president of the International Research Society for Public Management. He is associate editor of Public Administration Review and co-editor of the International Public Management Journal. He is also the founding co-editor of the Palgrave book series, Governing China in the 21st Century.

RICHARD ZECKHAUSER is the Frank P. Ramsey Professor of Political Economy, Kennedy School, Harvard University. He graduated from Harvard College (summa cum laude) and received his PhD there. He is an elected fellow of the Econometric Society, the Institute of Medicine (National Academy of Sciences), and the American Academy of Arts and Sciences. In 2014, he was named a Distinguished Fellow of the American Economic Association.
His contributions to decision theory and behavioral economics include the concepts of quality-adjusted life years (QALYs), status quo bias, betrayal aversion, and ignorance (states of the world unknown) as a complement to the categories of risk and uncertainty. Many of his policy investigations explore ways to promote the health of human beings, to help markets work more effectively, and to foster informed and appropriate choices by individuals and government agencies.

Chapter 13

JUI-FEN RACHEL LU is a professor in the Department of Health Care Management and dean of the College of Management at Chang Gung University in Taiwan, where she teaches comparative health systems, health economics, and healthcare financing. Her research focuses on equity issues in Taiwan’s healthcare system; the impact of the National Health Insurance program on the healthcare market and household consumption patterns; and comparative health systems in the Asia-Pacific region. She earned her BS from National Taiwan University, and her MS and ScD from Harvard University. Lu has served as a member of various government committees dealing with healthcare issues in Taiwan and is the recipient of various awards. She is the author of Health Economics, and has published papers in journals including Health Affairs, Medical Care, and Journal of Health Economics.

CHRISTINA PING is an undergraduate student in biology at Stanford University. Her interests lie in oncology and also in global health policy and economics, specifically regarding the accessibility and scalability of current cancer treatment technology, as well as insurance coverage for cancer treatment among different countries. Previously, Ping conducted clinical trials research at Memorial Sloan Kettering Cancer Center on tumor surveillance using blood biomarkers, and mechanisms of drug resistance in metastatic breast cancer patients. Upon graduation in June 2020, she will be working as a healthcare consultant as part of IQVIA’s consulting services team.

NANCY HANZHUO ZHANG is a graduate student in international policy at Stanford University. Her work and interests revolve around development economics, more specifically health, education, and trade in the emerging markets. Holding a BA in economics from UC Berkeley, Zhang has gained research and policy analysis experiences from the World Bank, the Bill & Melinda Gates Foundation, and the Economist Group. She has lived extensively in Belgium, China, and the United States, acquiring native fluency in French, English, and Chinese. In August 2020, she will start a position at
an economic litigation consulting firm to further enhance her quantitative and analytical skills in practice.

Chapter 14

**KAVITA SINGH** is an epidemiologist by training and works as a research scientist at the Public Health Foundation of India. Her research work has primarily focused on evaluating the long-term effectiveness and cost-effectiveness of a multicomponent quality improvement intervention in 1,146 patients with type 2 diabetes attending 10 tertiary care clinics in India and Pakistan, as part of the National Heart Lung Blood Institute–funded CARRS Trial. Recently, she has been awarded the Emerging Global Leader Award (K43 grant, 2019–24), funded by the National Institutes of Health, Fogarty International Centre, to conduct a research project that aims to develop and test the feasibility of a multicomponent cardiovascular quality improvement strategy for patients with established cardiovascular diseases in India.

**DORAIRAJ PRABHAKARAN** is professor of chronic disease epidemiology at the Public Health Foundation of India, and executive director of the Center for Chronic Disease Control. Dr. Prabhakaran has participated in and led several major international and national research studies, and heads one of only 11 funded global centers of excellence funded by the National Heart, Lung and Blood Institute and the UnitedHealth Group, the Center of Excellence – Center for Cardio-metabolic Risk Reduction in South Asia. Dr. Prabhakaran’s research has produced major insights into the epidemiology, developmental origin, and biomarkers of cardiovascular diseases (CVDs) and diabetes in India, practice patterns on acute coronary syndrome; translation research in CVDs, and development of low-cost combination drugs for primary and secondary prevention of CVDs in South Asia. Currently, he is working to establish a model surveillance system for CVD, evaluating the role of community health workers and mobile technology health programs to prevent and manage chronic diseases, undertaking two CVD cohorts, and involved in several clinical trials evaluating low-cost strategies.
As this book goes to press in April 2020, the world is in the midst of pandemic COVID-19 (coronavirus disease caused by SARS-CoV-2, a new coronavirus identified in 2019 with similarities to the SARS virus). First identified in Wuhan, People’s Republic of China, other parts of Asia and the rest of the world have been dealing with the pandemic, along with the social and economic costs of the measures needed to control its spread. While such a crisis may overshadow any of the more mundane and humdrum topics of healthy aging, it actually accentuates many of the themes highlighted in the chapters of this book: the importance of strengthening health systems, especially primary care; the need for policies across multiple sectors (e.g., public health, urban planning, transportation, education) that support healthy aging; the imperative of supporting the vulnerable and addressing disparities so that the blessings of longevity can be equitably enjoyed. Since those with chronic conditions and the frail elderly are most susceptible to severe disease or death from COVID-19 or other pathogens, including the seasonal influenza, societies need to focus on healthy aging to build resilience to the periodic threat of epidemics and pandemics, as well as to the day-to-day killers such as cardiovascular disease, stroke, and cancer. Moreover, measures to ensure social connectedness and civil society support for the vulnerable, whether during mandatory social distancing or not, can support mental health and healthy aging.

Only in the coming years will the health impacts of current crisis become evident, from the lives saved by proactive responses, to the numbers who suffered acute myocardial infarction, stroke, and other events from not keeping up with routine anti-hypertensive and anti-diabetic medications during “lockdown”; from the lessons learned in governance and public-private
partnerships for future crises, to the festering weaknesses in health financing and delivery never addressed; from the reduced traffic accidents from less commuting and reduced ill health from air pollution, to those who suffered catastrophic social and economic consequences from loss of livelihood or mental strain; from the many lives improved from better handwashing (perhaps fewer influenza deaths in future flu seasons?), to those lost from reversion to poorer hygiene when everyday life resumes its rush and complacency. May the suffering from this pandemic in Asia and beyond reinforce the interconnections between effective health systems and resilient civil society; the importance of transparent, scientific leadership that embraces Li Wenliang’s message that “there should be more than one voice in a healthy society”1 and the prudence and humanity of equitable investments in healthy aging, based on scientific analysis of the “value for money” spent on alternative policies or interventions. Perhaps from this crisis will emerge new ways of using telemedicine and leveraging other technologies to support the health of the rural, poor, and vulnerable; innovative protocols for bringing together resources in a public health emergency; and a renewed conviction that investment in strong health systems undergirds the very social and economic fiber of our societies.

We dedicate the research in this volume to all those suffering from COVID-19, especially those who have been denied the possibility of healthy aging.

I thank all the authors who contributed their research and policy expertise to the chapters of this book. I acknowledge and thank the numerous Stanford research assistants who assisted with various stages of the research included in this volume, including Pedro Gallardo, Rebecca Spencer, Karissa Dong, Helen Chen, Janice Zhang, Renata Starbird, Yanghe Iven Sha, Jillayne Ren, and others noted in the respective chapters. I extend special thanks to George Krompacky for his professionalism and patience during the editing and production work for this volume.

Finally, many thanks to my loving family for all your support. I dedicate my work on this volume to Adrian and Alanna: may you continue to thrive and cultivate healthy habits to enjoy long, full lives; and with love to Chris 可思, looking forward to healthy aging together.

Karen Eggleston
Stanford, California

---

Healthy Aging in Asia
Healthy Aging in Asia

Introduction

Karen Eggleston

Population aging and the economic (re)emergence of Asia—two of the most important phenomena of the twenty-first century—converge in the challenges Asian economies face in promoting healthy aging. The demographic transition from high to low fertility and mortality has been more rapid in much of Asia than in Europe and North America, and high-income East Asia leads the world in life expectancy and proportion of elderly, with middle-income China rapidly catching up at lower per capita income. Will most of the population benefit from longevity? And will these longer lives be healthy ones?

Much research reinforces the conclusion that investing in health brings economic benefits, when focused on priority health investments (Jamison et al. 2016). The probability that newborns will survive to age 90 has increased dramatically—in high-income countries from 4.8% in 1950 to 26.7% today and 50% by 2060, according to United Nations (UN) data (Eggleston and Mukherjee 2019). This triumph of longevity, along with low (frequently below-replacement) fertility, has important social and economic implications. Families, communities, and policies must adjust in ways that support healthy aging throughout the life course. For example, gains in longevity are increasingly accumulating at the end of life in conventional retirement years, rather than by reducing infant mortality (Eggleston and Fuchs 2012); therefore, working to older ages will be necessary. But extending work-lives is feasible only if the added years are healthy ones, and equitable only if the least advantaged also benefit from healthy aging. The great blessing of longer lives dims when later years are clouded by pain, disability, and loss of dignity.

How are health systems in Asia promoting evidence-based policies for healthy aging? What strategies have been tried to prevent noncommunicable
chronic diseases (NCDs), screen for early detection, raise quality of care, improve medication adherence, reduce unnecessary hospitalizations, and increase “value for money” in health spending? The chapters of this book contribute to the literature on how diverse economies of Asia are preparing for older population age structures and transforming health systems to support patients who will live with chronic disease for decades. Fourteen concise chapters are arranged by country and topic. Authors are social scientists and policymakers (e.g., Daejung Kim from Korea, and Maigeng Zhou, Min Yu, and colleagues from the central and provincial centers for disease control [CDCs] in China) sharing their empirical evidence and policy insights from recent and ongoing programs in each country or jurisdiction covered. They include experts in multiple disciplines and from multiple generations—from Professor Victor R. Fuchs, the “Dean of Health Economics,” now in his ninth decade, to students and recent graduates with fresh perspectives (Pedro Gallardo, Jason Li, Christina Ping, Zhi Ping Teo). Topics include precision health and personalized medicine in Japan; China’s evolving family doctor system and its national demonstration areas for chronic disease control; cancer disparities and public-private roles in Taiwan; and policies for healthy aging in Korea and India. Several chapters draw on research led by the Stanford Asia Health Policy Program on the net value of chronic disease management programs throughout Asia, starting with analysis of detailed longitudinal, patient-level data on diabetes management as a lens for understanding the net value of medical spending for patients with complicated chronic diseases across diverse health systems.

In this brief introduction to the book, I discuss patterns of demographic and epidemiologic change in the region and the contributions of each chapter, while highlighting the importance of addressing disparities in healthy aging.

Aging Asia

Regions vary in their historical experience of demographic transition. Some areas, such as the former Soviet Union or Eastern Europe, experienced a prolonged stagnation or even dramatic decline in life expectancy during the transformational recession accompanying the demise of socialism, followed in some cases by rapid improvement and greater variation in life span (Kornai and Eggleston 2001; Aburto and van Raalte 2018). In contrast, the Asian economies undergoing systemic transformation from central planning to market-based economies, China and Vietnam, have seen steady increases in life expectancy. Among high-income countries, Case and Deaton (2015) highlight “deaths of despair” (such as opioid overdoses) among the middle
class and middle-aged in the United States and their relationship to the recent U.S. decline in life expectancy. Japan, meanwhile, has achieved world-leading longevity, and South Korea also exceeds the average for high-income countries, as shown in figure 1.1.

**Figure 1.1** Life expectancy at birth, 2013 (in years)

```
```

Chapter 2 explores inequality in these longevity trends. Victor Fuchs and co-authors describe the distributions in age of death and their changes over time in three high-income countries of East Asia—Japan, South Korea, and Singapore—and the United States, compared with other high-income countries. The authors show that differences in life span between advantaged and disadvantaged groups generally decrease over time and with economic development, but remain large, especially among men. This greater survival gap among men echoes findings from many other studies. In Europe, for example, Permanyer et al. (2018) find that in Spain between 1960 and 2015 life expectancy increased for all, but with differences between the low and highly educated, especially among men. Chapter 2 concludes with a discussion of how policy might address inequalities by focusing on the causes of
death among youth and the middle-aged. Clearly, to support healthy aging, policymakers must pay attention to the entire life course.

Research can help to inform policy, not only by understanding patterns of change, but also by helping to monitor how societies adapt to aging along multiple dimensions. Some studies propose individual-based measures of healthy aging, while others focus on societal adaptation. For example, Chen et al. (2018) develop an “Aging Society” index that assesses the status of older populations across five specific domains, including productivity and engagement, well-being, equity, economic and physical security, and intergenerational cohesion, using data from the Organisation for Economic Cooperation and Development (OECD). They find that Japan lags behind Norway and Sweden, according to their index.

In this book, chapters 3, 4, and 5 explore dimensions of Japan’s policies for healthy aging, followed by expert accounts of South Korea and Hong Kong, all high-income economies with rapidly aging populations. The next five chapters provide different perspectives on China’s demographic change and health system reforms. As evident in figure 1.1, China truly embodies “multiple countries within one,” at least in terms of health. In figure 1.1, I disaggregate urban and rural China as if they are two separate countries. I illustrate internal disparities by showing the average life expectancy (with data from Zhou et al. [2016]) for the top four provinces (Shanghai, Beijing, Tianjin, and Zhejiang)—labeled “urban China”—compared to the average for the lowest four provinces (Tibet, Xinjiang, Qinghai, and Guizhou), which are labeled “rural China.” A few conclusions are inescapable. The 2013 gap in life expectancy between these proxies for urban and rural China—almost 10 life years—is equivalent to the gap between high- and middle-income countries. Residents of the top four provinces enjoy first-world health outcomes, virtually a different country from that of their compatriots in the lowest four provinces.
The Social Determinants of Health and Disparities in Healthy Aging

These wide regional and urban-rural disparities in health outcomes stem from a plethora of factors; access to healthcare is one, but much previous research (e.g., Fuchs 2004; Marmot 2015) highlights the importance of many (often highly correlated) non-medical factors, termed “social determinants of health,” including poverty, low educational attainment, and lack of local public goods (such as clean water, modern toilets, protection from harmful toxins, and community-wide control of vectors for infectious disease). Income, education, occupation, age, sex, marital status, and ethnicity are all correlated with health (Fuchs 2004). Moreover, the direction of causation is two-way: poor health can interfere with schooling and earning income, while poor education and low income can contribute to ill health and premature mortality. The virtuous cycle between better health and socioeconomic status has as its counterpart the vicious cycle of “illness-induced poverty” from causes ranging from childhood malnutrition to catastrophic medical spending.

To lay the foundation for healthy aging, societies must address these social determinants of health. Chapter 13, for example, discusses the many infection-caused cancers prevalent in China that contribute to urban-rural health disparities. Screening, as discussed in multiple chapters, can be effective in catching cancer at stages early enough to treat, as well as detecting other chronic diseases and avoiding disabling complications. But screening can also lead to false positives and over-treatment, as is potentially the case with the rapid increase in the incidence of thyroid cancer and its treatment (Vaccarella et al. 2016). Chapter 3 speaks to this theme by discussing Japan’s screening program for metabolic syndrome and other policies within the Healthy Japan 21 (2013–22) plan, as well as the importance of tobacco control.

Several chapters in this book describe policies aimed at promoting healthy behaviors and addressing the non-medical determinants of health. For example, chapter 4 discusses the political economy of “precision health” and its prospects in Japan. Chapter 8 discusses how China seeks to promote local innovations for control of risk factors leading to chronic disease. Here, Jianqun Dong and colleagues from the China National Center for Disease Control and Prevention describe China’s efforts to motivate local government

1 Du et al. (2018, 291) discuss the experience of Zhejiang Province, showing rapid increase in diagnosis of thyroid cancer with low and stable mortality, concluding “this increase in incidence might be due to increased diagnosis with advanced technology.” These trade-offs, as well as public and private roles, feature in chapter 13.
responsibility in the prevention and control of NCDs with inter-sectoral coordination and by promoting multi-department cooperation in the construction of national demonstration areas and National Health Cities.

Managing Chronic Disease

In addition to the social determinants of healthy aging, the role of appropriate healthcare remains quite important, especially in managing patients with chronic disease. Several chapters discuss economic research on diabetes and hypertension, two increasingly prevalent conditions in aging Asia.

In chapter 9, Min Yu of the Zhejiang provincial CDC and co-authors note that diabetes poses a critical public health issue in many countries, especially for health systems ill-prepared to manage chronic disease within primary care. China’s efforts to strengthen population health and primary care management for diabetes, especially in rural areas, deserve careful study and benchmarking to international experience to inform further progress. Improved prevention and control may not only improve patients’ quality of life, but also potentially save resources by reducing avoidable hospital admissions. The authors propose age- and sex-standardized medical expenditures on avoidable admissions, alongside the more standard metric of number of admissions, as a new way of measuring primary care management of diabetes and comparing progress over time and across regions.

Chapter 11 provides empirical evidence about hypertension control in China and its relationship with the country’s expansion of health insurance. Here, Jason Li argues that, given China’s growing elderly population and chronic disease burden, controlling hypertension has been called the most urgent and cost-effective public health strategy the country could pursue, and shows through his analysis of the “care cascade” that China still struggles with poor hypertension management: 59.7% of all hypertensives were diagnosed, 51.4% were treated, and only 22.3% achieved effective control. Insurance coverage depth remains shallow for many citizens; increased insurance generosity was associated with a higher likelihood of treatment but not of diagnosis and control. Thus, Li suggests that factors beyond insurance may be limiting the positive effect of insurance generosity on hypertension management, an area for evidence-based policy to contribute to better chronic disease control.

Confronting the challenges of aging societies will require thinking carefully about the value of investments in methods for managing chronic conditions. Several chapters in this book showcase careful empirical research on this theme. For example, chapter 3 summarizes research on the net value of
diabetes management in Japan; and the appendix provides detailed methods for others to consult in providing research evidence for other patient populations. This net value approach seeks to measure the productivity of resources devoted to chronic disease management, with detailed patient-level data to include the monetary value of improved health outcomes. As Dunn and Fernando (2019) argue, “a complete understanding of the growth trends in the medical care sector, as well as our overall economy, hinges on properly accounting for quality alongside costs.” Eggleston, Grossman, and Cutler (2004) suggest that productivity research could be considered the “genome” of healthcare delivery innovation, given its foundational role in guiding reforms of healthcare delivery systems to achieve quality and efficiency.

Indeed, careful research can help society to avoid across-the-board cost control measures that stifle healthcare innovations that would deliver health improvement at a reasonable cost, or even cut cost. Chapter 7 provides another valuable perspective in this line of research.

**Healthcare Access and Quality: Raising Averages, Addressing Disparities**

The contributors to this volume also point to health system innovation beyond specific chronic disease control measures—innovation aimed to to improve healthcare more generally and to reduce inequality. Disparities in healthcare access and quality remain vital policy priorities, especially for large, diverse countries such as India and China.

Ethical challenges are the focus of several studies of health sector reforms. For example, Kornai and Eggleston (2001) argue that reforms of health sectors in transition economies should promote individual sovereignty and choice, on the one hand, while assuring social solidarity—i.e., helping the suffering, the troubled, and the disadvantaged—on the other. These two ethical principles have their counterparts in the phenomena of innovation and shortage (or access): can a health system sustain both choice (i.e., allowing the wealthy to purchase health improvements) and solidarity to provide access to those same health improvements for those less fortunate?

Science, population health, and economic development, although uneven, have expanded the possibilities for all; social policies determine how soon and how completely those same possibilities for healthy longevity are made available to those less fortunate. Angus Deaton (2013) emphasizes a similar point: innovations, first in population health and later in medical care, increased inequality but also brought progress with “trickle down” access
for the poor. Indeed, this idea that innovations first accessed by the rich eventually diffuse to the poor has been called the “inverse equity hypothesis,” and seems to apply to multiple cases (e.g., Lee et al. [2015] on cancer screening). Vaccines are one of the most cost-effective technologies for health over the life course (Bloom 2018), yet the net benefit of their use for specific populations remains a critical policy question.

Policies to assist countries in responding effectively to population aging should give disproportionate weight and financial support to speeding up the inverse equity diffusion process to narrow health and healthcare inequalities, such as between rural and urban areas or between the poor and the non-poor. This lesson is highlighted in multiple chapters of this book, with detailed experiences and policies in various Asian economies illustrating progress and the challenges of equitable access to technologies for healthy aging, especially acute for low- and middle-income countries.

For measuring disparities, new metrics have also been developed that could be refined and extended over time. For example, a recent study develops the “Healthcare Access and Quality” (HAQ) index, which measures premature mortality from causes preventable by access to high-quality healthcare (Fullman et al. 2018). According to this metric (figure 1.2), India improved significantly between 1990 and 2016, but is still working to catch up with Indonesia, Vietnam, and Brazil. China’s rapid improvement in access and quality is evident from the fact that even China’s lowest region in 2016 was above the 1990 national median. Among 195 countries and territories, China shows the highest absolute change in the HAQ Index during 2000–16, overtaking Brazil and approximating South Korea in 2000. China’s HAQ index in 2016 was the highest among all countries with the same or lower medical spending per capita.

Despite this progress, sizable disparities remain in both health and healthcare within large low- and middle-income countries such as China and India. For example, although China achieved universal health coverage and improved healthcare utilization in both rural and urban areas over the past two decades, there are still substantial inter-regional gaps in service coverage, availability, and affordability. To illustrate, the 43-point regional disparity in HAQ within China (i.e., between Beijing and Tibet) is the equivalent of the difference between Iceland (ranked highest in the world) and North Korea. India also exhibited huge disparities—between Goa and Assam is a 30.8-point difference—whereas Japan recorded the smallest range in subnational HAQ performance in 2016 (a 4.8-point difference). Fullman et al. (2018) also note fast improvements in healthcare access and quality in southeast Asia.
To improve healthcare access and quality, health system innovations play an important role. Several chapters discuss such efforts in aging Asia. For example, chapter 10 on the family doctor system in China describes the many efforts to re-orient China’s health service delivery system away from crowding at tertiary hospitals and establish reliable systems for community-based care.

Another aspect of health system adjustment to aging involves the role of the public and private sectors in delivering health services and providing long-term care to the frail elderly. Public needs far outstrip the abilities of the government alone to deliver, including the broad array of social services that support healthy aging. These are the topics of two chapters. In chapter 12, Donahue and co-authors report results from a survey of 17 medium-sized cities in China on how local governments are seeking ways to create public value through contracting with the private sector and collaborative arrangements with some shared discretion, what the authors label “collaborative governance.” The chapters on Hong Kong, Korea, and India all touch upon different roles of public and private actors in each system. And in chapter 13 Eggleston, Lu, Ping, and Zhang discuss how government and private actors take on complementary roles in addressing cancer as a leading cause of death, from drug discovery and development, to negotiating drug prices on insurance formularies, to delivering innovative target therapies.

Demographic changes interact with new technologies, such as personalized medicine therapies, to challenge the sustainable financing of medical care. Hokuto Asano, in chapter 5, focuses on this issue. He explains Japan’s
policies regarding personalized and precision medicine, including data collection, policy support, and how insurance coverage for new therapies works in Japan, comparing four drugs and companion diagnostic tests to their coverage and pricing in the United Kingdom. He also notes the importance of cost-effectiveness analyses in this process. Cautious optimism could be warranted regarding the power of innovation to produce both “miracle drugs” and the new approaches to financing and payment that will spread their benefits more widely (Eggleston 2018).

In sum, the contributors to this volume provide detailed empirical evidence and rich policy experience, covering multiple aspects of policy initiatives for healthy aging in health systems as diverse as those of the cities Singapore and Hong Kong to large economies such as Japan, India, and China. I thank the authors for their contributions and hope you, the reader, will find our work useful.
References


